Xoma and Novartis restructure agreement
This article was originally published in Scrip
Xoma and Novartis have restructured their agreement involving six development programmes. Novartis will pay Xoma $6.2 million up front, fund all future R&D related to the six programmes, and reduce Xoma's existing debt by $7.5 million. It will pay Xoma up to $14 million in milestones and double-digit royalty rates in exchange for control of HCD122, a human monoclonal antibody that targets CD40, and one other programme. HCD122 is currently in Phase Ib/IIa trials for the treatment of lymphoma and a Phase I trial for the treatment of multiple myeloma. Novartis gains the right to expand the development of these two programmes into additional indications outside oncology. The restructuring of the deal will allow Xoma to focus on proprietary projects such as Xoma 052, an anti-inflammatory drug candidate for the treatment of multiple diseases, it says.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.